Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase

Journal of Medicinal Chemistry

Volumn 40, Issue 12, 1997, Pages 1886-1893

  Stevens, Malcolm F G ^a   Phillip, Keith S ^b   Rathbone, Daniel L ^c   O'Shea, Dennis M ^c   Queener, Sherry F ^d   Schwalbe, Carl H ^b   Lambert, Peter A ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c Aston Molecules Ltd   (United Kingdom)

^d INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 [3 [3 [2 (ACETYLOXY)ETHYL] 3 BENZYLTRIAZEN 1 YL] 4 CHLOROPHENYL] 6 ETHYLPYRIMIDINE; 2,4 DIAMINO 5 [4 CHLORO 3 (3,3 DIMETHYLTRIAZEN 1 YL)PHENYL] 6 ETHYLPYRIMIDINE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; PYRIMETHAMINE; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; ENZYME SPECIFICITY; MINIMUM INHIBITORY CONCENTRATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; X RAY CRYSTALLOGRAPHY;

ANIMALS; CHEMISTRY, PHYSICAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; FOLIC ACID ANTAGONISTS; LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PNEUMOCYSTIS; PYRIMIDINES; RATS; SOLUBILITY; TETRAHYDROFOLATE DEHYDROGENASE; TRIAZENES;

EID: 0030951939     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970050n     Document Type: Article

References (36)

1. Stevens, M. F. G.; Baig, G. U.; Gate, E. N.; Wheelhouse, R. T. Structural studies on bioactive compounds. Part 27. Chemistry of the immunomodulatory agent bropirimine. Anti-Cancer Drug Des. 1995, 10, 215-226.
2. McKenzie, R.; Travis, W. D.; Dolan, S. A.; Pittaluca, S.; Feurstein, I. M.; Shelhamer, J.; Yarchoan, R.; Mansur, H. The causes of death in patients with human immunodeficiency virus infection: a clinical and pathological study with emphasis on the role of pulmonary diseases. Medicine 1991, 70, 326-343.
3. Miller, R. F.; Mitchell, D. M. AIDS and the lung: Update 1995; 1 - Pneumocystis carinii pneumonia. Thorax 1995, 50, 191-200.
4. Kovacs, J. A.; Allegra, C. J.; Beaver, J.; Boardman, D.; Lewis, M.; Parillo, J. E.; Chabner, B.; Mansur, H. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii. Potential for screening therapeutic agents. J. Infect. Dis. 1989, 160, 312-320.
5. Southerland, W. M. A molecular model of the folate binding site of Pneumocystis carinii dihydrofolate reductase. J. Comput.-Aided Drug Des. 1994, 8, 113-122.
6. Champness, J. N.; Achari, A.; Ballatine, S. P.; Bryant, P. K.; Delves, C. J.; Stammers, D. K. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 Å resolution. Structure 1994, 2, 915-924.
7. Glatt, A. E.; Chirgwin, K. Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch. Intern. Med. 1990, 150, 271-279.
8. Queener, S. F. New drug developments for opportunistic infections in immuno-suppressed patients: Pneumocystis carinii. J. Med. Chem. 1995, 38, 4739-4759.
9. Piper, J. R.; Johnson, C. A.; Krauth, C. A.; Carter, R. L.; Hosmer, C. A.; Queener, S. F.; Borotz, S. E.; Pfefferkorn, E. R. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. J. Med. Chem. 1996, 39, 1271-1280.
10. (a) Rosowsky, A.; Forsch, R. A.; Queener, S. F. 2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1995, 38, 2615-2620.
11. (b) Gangjee, A.; Zhu, Y.; Queener, S. F.; Francom, P.; Broom, A. D. Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii. J. Med. Chem. 1996, 39, 1836-1845.
12. Bliss, E. A.; Griffin, R. J.; Stevens, M. F. G. Structural studies on bioactive compounds. Part 5. Synthesis and properties of 2,4-diaminopyrimidine dihydrofolate reductase inhibitors bearing lipophilic azido groups. J. Chem. Soc., Perkin Trans. 1 1987, 2217-2228.
13. Stevens, M. F. G.; Griffin, R. J.; Wong, S. K. The aromatic azido group in anti-cancer drug design: application in the development of novel lipophilic dihydrofolate reductase inhibitors. Anti-Cancer Drug Des. 1987, 2, 311-318.
14. Stuart, N. S. A.; Crawford, S. M.; Blackledge, G. R. P.; Newlands, E. S.; Slack, J. A.; Hoffman, R.; Stevens, M. F. G. A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES) - a new dihydrofolate reductase inhibitor. Cancer Chemother. Pharmacol. 1989, 23, 308-310.
15. Griffin, R. J.; Meek, M. A.; Schwalbe, C. H.; Stevens, M. F. G. Structural studies on bio-active compounds. Part 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethy]pyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line. J. Med. Chem. 1989, 32, 2468-2474.
16. Denny, B. J.; Ringan, N. S.; Schwalbe, C. H.; Lambert, P. A.; Meek, M. A.; Griffin, R. J.; Stevens. Structural studies on bioactive compounds. Part 8. Molecular modeling and crystallographic studies on methylbenzoprim, a potent inhibitor of dihydrofolate reductase. J. Med. Chem. 1992, 35, 2315-2320.
17. Broughton, M. C.; Queener, S. F. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrob. Agents Chemother. 1991, 35, 1348-1355.
18. Chio, L.-C.; Queener, S. F. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1993, 37, 1914-1923.
19. Bartlett, M. S.; Shaw, M. M.; Navaran, P.; Smith, J. W.; Queener, S. F. Evaluation of potent inhibitors of of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Antimicrob. Agents Chemother. 1995, 39, 2436-2441.
20. Preussman, R.; Druckrey, H.; Ivankovic, S.; von Hodenberg, A. Chemical structure and carcinogenicity of aliphatic hydrazo-, azo and azoxy compounds and of triazenes, potential in vivo alkylating agents. Ann. N.Y. Acad. Sci. 1969, 163, 697-714.
21. Connors, T. A.; Goddard, P. M.; Merai, K.; Ross, W. C. J.; Wilman, D. E. V. Tumour inhibitory triazenes: structural requirements for an active metabolite. Biochem. Pharmacol. 1976, 25, 241-246. Gescher, A.; Threadgill, M. D. The metabolism of triazene antitumour drugs. Pharmac. Ther. 1987, 32, 191-205.
22. Connors, T. A.; Goddard, P. M.; Merai, K.; Ross, W. C. J.; Wilman, D. E. V. Tumour inhibitory triazenes: structural requirements for an active metabolite. Biochem. Pharmacol. 1976, 25, 241-246. Gescher, A.; Threadgill, M. D. The metabolism of triazene antitumour drugs. Pharmac. Ther. 1987, 32, 191-205.
23. Gescher, A.; Hickman, J. A.; Simmonds, R. J.; Stevens, M. F. G.; Vaughan, K. α-Hydroxylated derivatives of antitumour dimethyltriazenes. Tetrahedron Lett. 1978, 5041-5044; Kolar, G. F.; Maurer, M.; Wildschütte, M. 5-(3-Hydroxymethyl-3-methyltriazeno)imidazole-4-carboxamide (DIC, DTIC, NSC 45388). Cancer Lett. 1980, 10, 241-253.
24. Gescher, A.; Hickman, J. A.; Simmonds, R. J.; Stevens, M. F. G.; Vaughan, K. α-Hydroxylated derivatives of antitumour dimethyltriazenes. Tetrahedron Lett. 1978, 5041-5044; Kolar, G. F.; Maurer, M.; Wildschütte, M. 5-(3-Hydroxymethyl-3-methyltriazeno)imidazole-4-carboxamide (DIC, DTIC, NSC 45388). Cancer Lett. 1980, 10, 241-253.
25. Vaughan, K.; Stevens, M. F. G. Monoalkyltriazenes. Chem. Soc. Rev. 1978, 7, 377-397.
26. Denny, B. J.; Wheelhouse, R. T.; Stevens, M. F. G.; Tsang, L. L. H.; Slack, J. A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994, 33, 9045-9051.
27. 1H nuclear magnetic resonance spectroscopy. J. Chem. Soc., Perkin Trans. 1 1987, 2229-2234.
28. Johnson, C. K. ORTEP. Oak Ridge Thermal-Ellipsoid Plot Program. Report ORNL-5136; Oak Ridge National Laboratory: Oak Ridge, TN, 1976.
29. Fronczek, F. R.; Hansch, C.; Watkins, S. F. p-(3,3-Dimethyl-1-triazeno)benzonitrile. Acta Crystallogr. 1988, C44, 1651-1653.
30. Schwalbe, C. H.; Cody, V. Structural studies of antifolate drugs. In Chemistry and Biology of Pteridines; Blair, J. A., Ed.; Walter de Gruyter: Berlin, 1983; pp 511-515.
31. 19F NMR observation of the conformational selection of optically active rotamers of the antifolate compound fluoronitropyrimethamine bound to the enzyme dihydrofolate reductase. FEBS Lett. 1988, 240, 201-204.
32. Birdsall, B.; Tendler, S. J. B.; Arnold, J. R. P.; Feeney, J.; Griffin, R. J.; Carr, M. D.; Thomas, J. A.; Roberts, G. C. K.; Stevens, M. F. G. NMR studies of multiple conformations in complexes of Lactobacillus casei dihydrofolate reductase with analogues of pyrimethamine. Biochemistry 1990, 29, 9660-9667.
33. Then, R. L.; Hartman, P. G.; Kompis, I.; Santi, D. Selective inhibition of dihydrofolate reductase from problem human pathogens. In Chemistry and Biology of Pteridines and Folates; Ayling, J. E., et al., Eds.; Plenum Press: New York, 1993; pp 533-536.
34. Main, P.; Germain, G.; Woolfson, M. M. MULTAN 84 - a computer program for the automatic solution of crystal structures from X-ray diffraction data. Universities of York and Louvain, 1984.
35. Sheldrick, G. M. SHELXL-93. Program for the refinement of crystal structures from diffraction data. University of Göttingen, 1993.
36. Jackson, H. C.; Colthurst, D.; Hancock, V.; Marriott, M. S.; Tuite, M. F. No detection of characteristic fungal protein elongation factor EF-3 in Pneumocystis carinii. J. Infect. Dis. 1991, 163, 675-677.